Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16573650 | 0.88 | ALDH1A1 (0.47) | ALDH1A1CES2CES1ADRB2ADRB1 | |
| SCHEMBL1243731 | 0.84 | ALDH1A1 (0.51) | ALDH1A1CES2CES1ADRB2ADRB1 | |
| SCHEMBL10099631 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CES2CES1ADRB2ADRB1 | |
| SCHEMBL5494998 | 0.81 | ALDH1A1 (0.49) | ALDH1A1CES2CES1ADRB2ADRB1 | |
| SCHEMBL12644384 | 0.81 | ALDH1A1 (0.54) | ALDH1A1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL7709824 | 0.78 | ALDH1A1 (0.44) | ALDH1A1CES2CES1ADRB2ADRB1 | |
| SCHEMBL16573651 | 0.78 | ALDH1A1 (0.41) | ALDH1A1CES2CES1ADRB2ADRB1 | |
| SCHEMBL7516017 | 0.77 | — | — | |
| SCHEMBL11374216 | 0.76 | ALDH1A1 (0.49) | ALDH1A1CES2CES1ADRB2ADRB1 | |
| SCHEMBL1966553 | 0.76 | ALDH1A1 (0.45) | ALDH1A1CES2CES1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762386-B1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20220056033-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11124515-B2 | Adenosine receptor antagonists and uses thereof | TEON THERAPEUTICS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210163483-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210040097-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2019173380-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163483-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 817/4885CES2 967/4885CES1 1176/4885 |
| US-20220056033-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 817/4885CES2 967/4885CES1 1176/4885 |
| US-11124515-B2 | Adenosine receptor antagonists and uses thereof | ADORA2B, ADORA2A, ADORA3 | ALDH1A1 634/4885CES2 1470/4885CES1 1052/4885 |
| US-20210040097-A1 | ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 817/4885CES2 967/4885CES1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.